

TRICARE Prior Authorization Request Form for  
ivacaftor/lumacaftor (Orkambi)



7231 Parkway Drive, Suite 100, Hanover, MD 21076

# USFHP Pharmacy Prior Authorization Form

**FAX Completed Form and  
Applicable Progress Notes to:  
(410) 424-4037**

To be completed by Requesting provider	
Drug Name:	Strength:
Dosage/Frequency (SIG):	Duration of Therapy:

**Questions?** Contact the Pharmacy Dept at: (888) 819-1043, option 4

Clinical Documentation must accompany form in order for a determination to be made.

Prior authorization does not expire.

**Step 1 Please complete patient and physician information (please print):**

<b>1</b> Patient Name:	_____	Physician Name:	_____
Address:	_____	Address:	_____
Sponsor ID #	_____	Phone #:	_____
Date of Birth:	_____	Secure Fax #:	_____

**Step 2 Please complete the clinical assessment:**

<b>1. Is Orkambi prescribed for the treatment of cystic fibrosis?</b>  <b>Note: Non-FDA-approved uses are not approved, including: patients who are heterozygous for the F508del mutation in the CFTR gene.</b>	<input type="checkbox"/> Yes Proceed to Question 2	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
	<input type="checkbox"/> Granules Proceed to Question 3	<input type="checkbox"/> Tablets Proceed to Question 5
<b>2. Is this request for Orkambi granules or tablets?</b>	<input type="checkbox"/> 1 to 5 years of age - proceed to Question 6 <input type="checkbox"/> Older than 5 years of age – proceed to Question 4 <input type="checkbox"/> Younger than 1 year of age – <b>STOP Coverage not approved</b>	
<b>3. What is the patient's age</b>		
<b>4. Does the patient have documented swallowing difficulties?</b>	<input type="checkbox"/> Yes Proceed to Question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>5. Is the patient 6 years of age or older?</b>	<input type="checkbox"/> Yes Proceed to Question 6	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>6. Is the patient homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene as detected by an FDA-approved test?</b>	<input type="checkbox"/> Yes Proceed to Question 7	<input type="checkbox"/> No <b>STOP</b> Coverage not approved
<b>7. Will the patient be using Orkambi granules along with Orkambi tablets?</b>	<input type="checkbox"/> Yes <b>STOP</b> Coverage not approved	<input type="checkbox"/> No Proceed to Question 8

